Dublin, Feb. 22, 2018 (GLOBE NEWSWIRE) -- The "Rosacea - Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering. 'Rosacea - Pipeline Insight, 2018' report offers ...
Many B2B marketers have been struggling with tough challenges, such as budget constraints and incomplete data, as they've tried to drive pipeline growth. That's according to a recent Pipeline360 ...
Zacks Investment Research on MSN
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?
Intellia Therapeutics NTLA has made good progress with the advancement of its in vivo candidate, lonvo-z (or, NTLA-2002), ...
AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology remains its core area, the company is also signing some early-stage deals ...
Narrow-moat Royalty Pharma’s first-quarter results were in line with our expectations. We are leaving our $52 fair value estimate unchanged and continue to believe the market is undervaluing Royalty ...
Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, will host an Innovation Webcast today at 8:30 a.m. ET to ...
Analyst Anthony Linton from Jefferies reiterated a Buy rating on Pembina Pipeline (PBA – Research Report) and keeping the price target at C$61.00. Pick the best stocks and maximize your portfolio: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback